Robert Talac: Is PRP Truly Autologous?
Robert Talac, Medical Director at Renaxis Regenerative Orthopedic Center, shared a post on LinkedIn:
“PRP Is Not Fully Autologous.
We should probably talk about that.
I’ve been in regenerative medicine for over 30 years.
For most of that time, PRP was widely accepted as the gold standard of autologous biologics.
I want to challenge that.
Here’s what’s actually in a standard PRP preparation:
- Citrate or EDTA anticoagulants (not from the patient)
- Bovine thrombin as an activator (not from thepatient)
- Calcium chloride to trigger clotting (not from the patient)
None of these are autologous. And it’s not a minor footnote.
EDTA and citrate disturb natural ionic homeostasis and alter cytokine profiles.
Bovine thrombin carries a documented immunogenicity risk, potentially triggering antibody responses against the patient’s own clotting factors.
This is not a fringe concern. It’s in the published data.
Platelet-Rich Fibrin (PRF), by contrast, uses no anticoagulant.
- Blood is drawn and immediately centrifuged.
- Clotting occurs through physiologic thrombin alone.
- No external activator, no foreign additive, no biochemical modification.
One caveat worth naming: many commercial PRF kits use silica or silicone-coated tubes as clot activators.
Those are foreign materials, too.
Which is why I use plain glass tubes (Bio-PRF) – the only truly additive-free option.
The result?
A dense autologous platelet-rich fibrin matrix. Nothing added. Nothing altered.
We’ve spent decades debating PRP activation protocols, platelet concentrations, and leucocyte ratios. Maybe the more important question is simpler:
If autologous therapy is the goal – is PRP actually”
Stay updated with Hemostasis Today.
-
Apr 20, 2026, 12:14Yanki Yarman: Linking Genetic Variants to Clinical Outcomes in Thrombosis
-
Apr 20, 2026, 12:09Syed Sibtain Raza: White Blood Cells – Understanding Morphology for Better Diagnosis
-
Apr 20, 2026, 11:23Bastu Odoka: Jehovah’s Witness News on Transfusion… and a Question Worth Asking
-
Apr 20, 2026, 11:15William Aird: A Physiological Approach to Anemia
-
Apr 20, 2026, 10:59Eric Topol: Is the Interferon Pathway a Key Driver of Inflammaging and Aging
-
Apr 20, 2026, 10:47Emmanuel J Favaloro: Emerging Perspectives on Extracellular Vesicles in Hemophilia
-
Apr 20, 2026, 10:21Pierpaolo Di Micco: Honored to Join the ESVM Congress in Lausanne
-
Apr 20, 2026, 08:17Heghine Khachatryan: Key Takeaways from Day 1 – WFH 2026 World Congress
-
Apr 20, 2026, 08:10Justin Nelson-Deering։ Celebrating World Hemophilia Day in Pediatric Care